Search

  • HOME
  • Search
Review
1749
Eating, diet, and nutrition for the treatment of non-alcoholic fatty liver disease
Georg Semmler, Christian Datz, Michael Trauner
Clin Mol Hepatol. 2023;29(Suppl):S244-S260.   Published online December 14, 2022
View: 3963   Download: 263  Citations: 6
1710
Hepatocellular carcinoma surveillance in patients with non-alcoholic fatty liver disease
Karim Seif El Dahan, Darine Daher, Amit G. Singal
Clin Mol Hepatol. 2023;29(Suppl):S207-S219.   Published online September 14, 2022
View: 6063   Download: 147  Citations: 5
1729
Causes and risk profiles of mortality among individuals with nonalcoholic fatty liver disease
Peter Konyn, Aijaz Ahmed, Donghee Kim
Clin Mol Hepatol. 2023;29(Suppl):S43-S57.   Published online November 22, 2022
View: 2614   Download: 142  Citations: 9
Correspondence
Correspondence on Letter regarding “Risk factors in nonalcoholic fatty liver disease”
Eileen L. Yoon, Dae Won Jun
Clin Mol Hepatol. 2023;29(4):1050-1051.   Published online August 29, 2023
View: 639   Download: 19
Correspondence on Letter regarding “Evidence-based hyponatremia management in liver disease”
Ji Young Ryu, Seon Ha Baek, Sejoong Kim
Clin Mol Hepatol. 2023;29(4):1048-1049.   Published online August 14, 2023
View: 909   Download: 24
Letter to the Editor
Letter regarding “Risk factors in nonalcoholic fatty liver disease”
Abhijit Pratap, Umesh More, Pradnya Phalak, Anita Deshmukh
Clin Mol Hepatol. 2023;29(4):1046-1047.   Published online August 22, 2023
View: 750   Download: 29  Citation: 1
Review
1835
Evidence-based hyponatremia management in liver disease
Ji Young Ryu, Seon Ha Baek, Sejoong Kim
Clin Mol Hepatol. 2023;29(4):924-944.   Published online June 5, 2023
View: 1731   Download: 179  Citations: 3
1798
Safety considerations for withdrawal of nucleos(t)ide analogues in patients with chronic hepatitis B: First, do no harm
Yao-Chun Hsu, Cheng-Hao Tseng, Jia-Horng Kao
Clin Mol Hepatol. 2023;29(4):869-890.   Published online March 14, 2023
View: 1702   Download: 139  Citations: 3
1791
Hepatitis B core-related antigen: A novel and promising surrogate biomarker to guide anti-hepatitis B virus therapy
Takako Inoue, Takehisa Watanabe, Yasuhito Tanaka
Clin Mol Hepatol. 2023;29(4):851-868.   Published online March 9, 2023
View: 5394   Download: 285  Citation: 1
Special Review
1854
Waiting for the changes after the adoption of steatotic liver disease
Eileen L. Yoon, Dae Won Jun
Clin Mol Hepatol. 2023;29(4):844-850.   Published online September 6, 2023
View: 1001   Download: 127
1849
Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity
Gi-Ae Kim, Joon Ho Moon, Won Kim
Clin Mol Hepatol. 2023;29(4):831-843.   Published online August 25, 2023
View: 1805   Download: 234  Citations: 3
Original Article
1822
Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients
Xiaoning Wu, Xiaoqian Xu, Jialing Zhou, Yameng Sun, Huiguo Ding, Wen Xie, Guofeng Chen, Anlin Ma, HongXin Piao, Bingqiong Wang, Shuyan Chen, Tongtong Meng, Xiaojuan Ou, Hwai-I Yang, Jidong Jia, Yuanyuan Kong, Hong You
Clin Mol Hepatol. 2023;29(3):747-762.   Published online May 10, 2023
View: 1464   Download: 110
Review
1781
Acute hepatitis C virus infection: clinical update and remaining challenges
Chen-Hua Liu, Jia-Horng Kao
Clin Mol Hepatol. 2023;29(3):623-642.   Published online February 20, 2023
View: 2876   Download: 297  Citations: 5
Editorial
Non-obese or lean nonalcoholic fatty liver disease matters, but is it preventable or inevitable in light of its risk factors?
Heejoon Jang, Won Kim
Clin Mol Hepatol. 2023;29(2):381-383.   Published online March 9, 2023
View: 1974   Download: 70  Citation: 1
Lean vs. obese phenotypes of nonalcoholic fatty liver disease: similar or different?
Ho Soo Chun, Minjong Lee
Clin Mol Hepatol. 2023;29(2):377-380.   Published online March 9, 2023
View: 1746   Download: 84  Citation: 1
Challenges in translating clinical guidelines into real-life practice for management of hepatocellular carcinoma in Taiwan
San-Chi Chen
Clin Mol Hepatol. 2023;29(2):352-354.   Published online March 20, 2023
View: 1810   Download: 54
Management of hepatocellular carcinoma in China: Seeking common grounds while reserving differences
Tian Yang, Ming-Da Wang, Xin-Fei Xu, Chao Li, Han Wu, Feng Shen
Clin Mol Hepatol. 2023;29(2):342-344.   Published online March 16, 2023
View: 1943   Download: 50
What should be done to reduce the discrepancy between guidelines and real-life practice for hepatocellular carcinoma in Korea?
Min Kyung Park, Yoon Jun Kim
Clin Mol Hepatol. 2023;29(2):332-334.   Published online March 16, 2023
View: 1743   Download: 39
Review
1797
Overview of Asian clinical practice guidelines for the management of hepatocellular carcinoma: An Asian perspective comparison
Yuri Cho, Bo Hyun Kim, Joong-Won Park
Clin Mol Hepatol. 2023;29(2):252-262.   Published online March 10, 2023
View: 3003   Download: 202  Citations: 4
1758
Clinical practice guidelines and real-life practice on hepatocellular carcinoma: A the Hong Kong perspective
Rex Wan-Hin Hui, Lung-Yi Mak, Tan-To Cheung, Victor Ho-Fun Lee, Wai-Kay Seto, Man-Fung Yuen
Clin Mol Hepatol. 2023;29(2):217-229.   Published online December 28, 2022
View: 3729   Download: 218  Citations: 5
1761
Clinical practice guideline and real-life practice in hepatocellular carcinoma: A Korean perspective
Myung Ji Goh, Dong Hyun Sinn, Jong Man Kim, Min Woo Lee, Dong Ho Hyun, Jeong Il Yu, Jung Yong Hong, Moon Seok Choi
Clin Mol Hepatol. 2023;29(2):197-205.   Published online January 5, 2023
View: 3134   Download: 213  Citations: 6
Correspondence
Correspondence on Editorial regarding “Impact of nationwide hepatocellular carcinoma surveillance on the prognosis in patients with chronic liver disease”
Won Sohn, Yong-Han Paik
Clin Mol Hepatol. 2023;29(1):182-184.   Published online November 22, 2022
View: 2195   Download: 35
Letter to the Editor
Correspondence on Letter regarding “Impacts of muscle mass dynamics on prognosis of outpatients with cirrhosis”
Tae Hyung Kim, Young Kul Jung, Hyung Joon Yim
Clin Mol Hepatol. 2023;29(1):173-175.   Published online November 15, 2022
View: 2119   Download: 39  Citation: 1
Original Article
1698
Hepatocellular carcinoma incidence is decreasing in Korea but increasing in the very elderly
Young Eun Chon, Seong Yong Park, Han Pyo Hong, Donghee Son, Jonghyun Lee, Eileen Yoon, Soon Sun Kim, Sang Bong Ahn, Soung Won Jeong, Dae Won Jun
Clin Mol Hepatol. 2023;29(1):120-134.   Published online August 12, 2022
View: 3512   Download: 176  Citations: 11
Review
1668
Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: A narrative review
Lei Miao, Jing Xu, Giovanni Targher, Christopher D Byrne, Ming-Hua Zheng
Clin Mol Hepatol. 2022;28(4):725-738.   Published online March 14, 2022
View: 3943   Download: 236  Citations: 6
Original Article
1677
Reappraisal of sepsis-3 and CLIF-SOFA as predictors of mortality in patients with cirrhosis and infection presenting to the emergency department: A multicenter study
Ji Hyun Kim, Baek Gyu Jun, Minjong Lee, Hye Ah Lee, Tae Suk Kim, Jeong Won Heo, Da Hye Moon, Seong Hee Kang, Ki Tae Suk, Moon Young Kim, Young Don Kim, Gab Jin Cheon, Soon Koo Baik, Dong Joon Kim, Dae Hee Choi
Clin Mol Hepatol. 2022;28(3):540-552.   Published online May 6, 2022
View: 3482   Download: 106  Citation: 1
1675
Discovery of dipeptidyl peptidase-4 inhibitor specific biomarker in non-alcoholic fatty liver disease mouse models using modified basket trial
Ju Hee Oh, Dae Won Jun, Hye Young Kim, Seung Min Lee, Eileen L. Yoon, Jungwook Hwang, Jung Hwan Park, Hanbi Lee, Wankyu Kim, Hyunsung Kim
Clin Mol Hepatol. 2022;28(3):497-509.   Published online April 28, 2022
View: 4586   Download: 149  Citations: 2
Tenofovir alafenamide treatment may not worsen the lipid profile of chronic hepatitis B patients: A propensity score-matched analysis
Joonho Jeong, Jung Woo Shin, Seok Won Jung, Eun Ji Park, Neung Hwa Park
Clin Mol Hepatol. 2022;28(2):254-264.   Published online December 28, 2021
View: 4072   Download: 259  Citations: 13
1655
Galectin-3 inhibits cardiac contractility via a tumor necrosis factor alpha-dependent mechanism in cirrhotic rats
Ki Tae Yoon, Hongqun Liu, Jing Zhang, Sojung Han, Samuel S. Lee
Clin Mol Hepatol. 2022;28(2):232-241.   Published online January 5, 2022
View: 3746   Download: 99  Citations: 4
1623
Association between serum tumor necrosis factor-α and sarcopenia in liver cirrhosis
Ji Won Han, Da In Kim, Hee Chul Nam, U Im Chang, Jin Mo Yang, Do Seon Song
Clin Mol Hepatol. 2022;28(2):219-231.   Published online July 20, 2021
View: 17978   Download: 302  Citations: 10
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |

Clinical and
Molecular
Hepatology

Print ISSN: 2287-2728
Online ISSN: 2287-285X


Editorial Office
The Korean Association for the Study of the Liver
Room A1210, 53 Mapo-daero(MapoTrapalace, Dowha-dong), Mapo-gu, Seoul, 04158, Korea
TEL: +82-2-703-0051   FAX: +82-2-703-0071    E-mail: kasl@kams.or.kr
Copyright © The Korean Association for the Study of the Liver.         
COUNTER
TODAY : 1167
TOTAL : 1548167
Close layer